The report analyzes and forecasts the continuous manufacturing market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of continuous manufacturing, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major continuous manufacturing companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of continuous manufacturing upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of continuous manufacturing and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global continuous manufacturing market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the continuous manufacturing market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of continuous manufacturing market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Major players in the Continuous Manufacturing market are GEA Group AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bosch Packaging Technology (Germany), Coperion GmbH (Germany), and Glatt GmbH (Germany).
Report Segmentation:
Continuous Manufacturing Market, by Product
Continuous Manufacturing Market, by Application
Continuous Manufacturing Market, by End User
Continuous Manufacturing Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Continuous Manufacturing Market, By Therapeutics Type
7.1. Continuous Manufacturing Market, By Therapeutics Type, 2020-2030
7.1.1. Large Molecules
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Small Molecules
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Continuous Manufacturing Market, By Application Type
8.1. Continuous Manufacturing Market, By Application Type, 2020-2030
8.1.1. Finished Product Manufacturing
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. API Manufacturing
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Continuous Manufacturing Market, By Formulation Type
9.1. Continuous Manufacturing Market, By Formulation Type, 2020-2030
9.1.1. Solid Formulation
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Liquid & Semi-solid Formulation
9.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Continuous Manufacturing Market, By Mode Type
10.1. Continuous Manufacturing Market, By Mode Type, 2020-2030
10.1.1. In-House
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Contract
10.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Continuous Manufacturing Market, By Sales Type
11.1. Continuous Manufacturing Market, By Sales Type, 2020-2030
11.1.1. Preclinical
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. Clinical
11.1.2.1. Market Revenue and Forecast (2016-2030)
11.1.3. Commercial
11.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 12. Global Continuous Manufacturing Market, By Product Type
12.1. Continuous Manufacturing Market, By Application Type, 2020-2030
12.1.1. Integrated Systems
12.1.1.1. Market Revenue and Forecast (2016-2030)
12.1.2. Semi-continuous Systems
12.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 13. Global Continuous Manufacturing Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.1.2. Market Revenue and Forecast, By Application (2016-2030)
13.1.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.1.4. Market Revenue and Forecast, By Mode (2016-2030)
13.1.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.1.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.1.7. U.S.
13.1.7.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.1.7.2. Market Revenue and Forecast, By Application (2016-2030)
13.1.7.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.1.7.4. Market Revenue and Forecast, By Mode (2016-2030)
13.1.8. Market Revenue and Forecast, By Sales Type (2016-2030)
13.1.8.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.1.9. Rest of North America
13.1.9.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.1.9.2. Market Revenue and Forecast, By Application (2016-2030)
13.1.9.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.1.9.4. Market Revenue and Forecast, By Mode (2016-2030)
13.1.10. Market Revenue and Forecast, By Sales Type (2016-2030)
13.1.11. Market Revenue and Forecast, By Product Type (2016-2030)
13.1.11.1.
13.2. Europe
13.2.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.2.2. Market Revenue and Forecast, By Application (2016-2030)
13.2.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.2.4. Market Revenue and Forecast, By Mode (2016-2030)
13.2.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.2.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.2.7.
13.2.8. UK
13.2.8.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.2.8.2. Market Revenue and Forecast, By Application (2016-2030)
13.2.8.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.2.9. Market Revenue and Forecast, By Mode (2016-2030)
13.2.10. Market Revenue and Forecast, By Sales Type (2016-2030)
13.2.10.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.2.11. Germany
13.2.11.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.2.11.2. Market Revenue and Forecast, By Application (2016-2030)
13.2.11.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.2.12. Market Revenue and Forecast, By Mode (2016-2030)
13.2.13. Market Revenue and Forecast, By Sales Type (2016-2030)
13.2.14. Market Revenue and Forecast, By Product Type (2016-2030)
13.2.14.1.
13.2.15. France
13.2.15.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.2.15.2. Market Revenue and Forecast, By Application (2016-2030)
13.2.15.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.2.15.4. Market Revenue and Forecast, By Mode (2016-2030)
13.2.16. Market Revenue and Forecast, By Sales Type (2016-2030)
13.2.16.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.2.17. Rest of Europe
13.2.17.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.2.17.2. Market Revenue and Forecast, By Application (2016-2030)
13.2.17.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.2.17.4. Market Revenue and Forecast, By Mode (2016-2030)
13.2.18. Market Revenue and Forecast, By Sales Type (2016-2030)
13.2.18.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.3.2. Market Revenue and Forecast, By Application (2016-2030)
13.3.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.3.4. Market Revenue and Forecast, By Mode (2016-2030)
13.3.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.3.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.3.7. India
13.3.7.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.3.7.2. Market Revenue and Forecast, By Application (2016-2030)
13.3.7.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.3.7.4. Market Revenue and Forecast, By Mode (2016-2030)
13.3.8. Market Revenue and Forecast, By Sales Type (2016-2030)
13.3.9. Market Revenue and Forecast, By Product Type (2016-2030)
13.3.10. China
13.3.10.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.3.10.2. Market Revenue and Forecast, By Application (2016-2030)
13.3.10.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.3.10.4. Market Revenue and Forecast, By Mode (2016-2030)
13.3.11. Market Revenue and Forecast, By Sales Type (2016-2030)
13.3.11.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.3.12. Japan
13.3.12.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.3.12.2. Market Revenue and Forecast, By Application (2016-2030)
13.3.12.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.3.12.4. Market Revenue and Forecast, By Mode (2016-2030)
13.3.12.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.3.12.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.3.13. Rest of APAC
13.3.13.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.3.13.2. Market Revenue and Forecast, By Application (2016-2030)
13.3.13.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.3.13.4. Market Revenue and Forecast, By Mode (2016-2030)
13.3.13.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.3.13.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.4.2. Market Revenue and Forecast, By Application (2016-2030)
13.4.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.4.4. Market Revenue and Forecast, By Mode (2016-2030)
13.4.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.4.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.4.7. GCC
13.4.7.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.4.7.2. Market Revenue and Forecast, By Application (2016-2030)
13.4.7.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.4.7.4. Market Revenue and Forecast, By Mode (2016-2030)
13.4.8. Market Revenue and Forecast, By Sales Type (2016-2030)
13.4.9. Market Revenue and Forecast, By Product Type (2016-2030)
13.4.10. North Africa
13.4.10.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.4.10.2. Market Revenue and Forecast, By Application (2016-2030)
13.4.10.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.4.10.4. Market Revenue and Forecast, By Mode (2016-2030)
13.4.11. Market Revenue and Forecast, By Sales Type (2016-2030)
13.4.12. Market Revenue and Forecast, By Product Type (2016-2030)
13.4.13. South Africa
13.4.13.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.4.13.2. Market Revenue and Forecast, By Application (2016-2030)
13.4.13.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.4.13.4. Market Revenue and Forecast, By Mode (2016-2030)
13.4.13.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.4.13.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.4.14. Rest of MEA
13.4.14.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.4.14.2. Market Revenue and Forecast, By Application (2016-2030)
13.4.14.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.4.14.4. Market Revenue and Forecast, By Mode (2016-2030)
13.4.14.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.4.14.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.5.2. Market Revenue and Forecast, By Application (2016-2030)
13.5.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.5.4. Market Revenue and Forecast, By Mode (2016-2030)
13.5.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.5.6. Market Revenue and Forecast, By Product Type (2016-2030)
13.5.7. Brazil
13.5.7.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.5.7.2. Market Revenue and Forecast, By Application (2016-2030)
13.5.7.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.5.7.4. Market Revenue and Forecast, By Mode (2016-2030)
13.5.8. Market Revenue and Forecast, By Sales Type (2016-2030)
13.5.8.1. Market Revenue and Forecast, By Product Type (2016-2030)
13.5.9. Rest of LATAM
13.5.9.1. Market Revenue and Forecast, By Therapeutics Type (2016-2030)
13.5.9.2. Market Revenue and Forecast, By Application (2016-2030)
13.5.9.3. Market Revenue and Forecast, By Formulation (2016-2030)
13.5.9.4. Market Revenue and Forecast, By Mode (2016-2030)
13.5.9.5. Market Revenue and Forecast, By Sales Type (2016-2030)
13.5.9.6. Market Revenue and Forecast, By Product Type (2016-2030)
Chapter 14. Company Profiles
14.1. Thermo Fisher Scientific, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pall Corporation
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Applikon Biotechnology
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sartorius Stedim Biotech
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. GEA Group Aktiengesellschaft
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Corning Incorporated
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Merck KGaA
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Glatt GmbH
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Repligen Corporation.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eppendorf AG
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
14.11. Electrolab Biotech Ltd.
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives
14.12. Solesis Medical
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives
14.13. Scott Equipment Company
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives
14.14. L.B. Bohle
14.14.1. Company Overview
14.14.2. Product Offerings
14.14.3. Financial Performance
14.14.4. Recent Initiatives
14.15. LONZA
14.15.1. Company Overview
14.15.2. Product Offerings
14.15.3. Financial Performance
14.15.4. Recent Initiatives
14.16. 3M
14.16.1. Company Overview
14.16.2. Product Offerings
14.16.3. Financial Performance
14.16.4. Recent Initiatives
14.17. CellGenix GmbH
14.17.1. Company Overview
14.17.2. Product Offerings
14.17.3. Financial Performance
14.17.4. Recent Initiatives
14.18. Boehringer Ingelheim International GmbH
14.18.1. Company Overview
14.18.2. Product Offerings
14.18.3. Financial Performance
14.18.4. Recent Initiatives
14.19. Bio-Rad Laboratories
14.19.1. Company Overview
14.19.2. Product Offerings
14.19.3. Financial Performance
14.19.4. Recent Initiatives
14.20. Avantor, Inc.
14.20.1. Company Overview
14.20.2. Product Offerings
14.20.3. Financial Performance
14.20.4. Recent Initiatives
14.21. Ajinomoto Bio-Pharma
14.21.1. Company Overview
14.21.2. Product Offerings
14.21.3. Financial Performance
14.21.4. Recent Initiatives
14.22. GlaxoSmithKline
14.22.1. Company Overview
14.22.2. Product Offerings
14.22.3. Financial Performance
14.22.4. Recent Initiatives
14.23. Continuus Pharmaceuticals
14.23.1. Company Overview
14.23.2. Product Offerings
14.23.3. Financial Performance
14.23.4. Recent Initiatives
14.24. Arcinova
14.24.1. Company Overview
14.24.2. Product Offerings
14.24.3. Financial Performance
14.24.4. Recent Initiatives
14.25. Amgen
14.25.1. Company Overview
14.25.2. Product Offerings
14.25.3. Financial Performance
14.25.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers